

10649227
(10649227)

> d his

(FILE 'HOME' ENTERED AT 11:54:54 ON 04 JUN 2004)

FILE 'REGISTRY' ENTERED AT 11:55:06 ON 04 JUN 2004

L1 STRUCTURE uploaded

L2 3 S L1

L3 54 S L1 SSS FULL


FILE 'CAPLUS' ENTERED AT 11:56:04 ON 04 JUN 2004

L4 6 S L3

=> d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> d 1-6 bib abs hitstr

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:392324 CAPLUS

TI Preparation of alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolopyridines as
MAP kinases, in particular p38 kinase inhibitors

IN Dombroski, Mark A.; Letavic, Michael A.; McClure, Kim F.

PA Pfizer Inc, USA

SO U.S. Pat. Appl. Publ., 31 pp.


CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----------------------|-------|----------|-----------------|----------|
| ----- | ----- | ----- | ----- | ----- |
| PI US 2004092547 | A1 | 20040513 | US 2003-649227 | 20030827 |
| PRAI US 2002-407088P | P | 20020830 | | |
| GI | | | | |



AB . Title compds. I [wherein R1 = F; n = 2; R2 = alkyl, optionally substituted by halo, OH, alkoxy, and alkoxy carbonyl; with certain compds. absent; their pharmaceutically acceptable salts] were prepared as potent inhibitors of MAP kinases, preferably p38 kinase. For example, II was prepared by Pd-cross coupling of 6-(4-bromo oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine (preparation given) with 2,5-difluoroboronic acid in the presence of TEA/EtOH/H₂O. Selected I had an IC₅₀ <10 μM in the TNF-α and MAPKAP in vitro assays, and an EC₅₀ <50 mg/kg in the in vivo TNFα assay. I are useful for treating inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in

IT stroke of heart attack, autoimmune diseases and other disorders.
66981-02-0P, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine
RL: PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(p38 kinase inhibitor; preparation of alkylidifluorophenyloxazolyltriazolopyridines as MAP kinases, in particular p38 kinase inhibitors)


RN 668981-02-0 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



IT **459448-00-1P 668981-03-1P**, 6-[4-(2,6-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine
668981-04-2P, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine hydrochloride **668981-05-3P**,
6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine methanesulfonate **668981-06-4P**, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine p-toluenesulfonate **668981-07-5P**, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine sulfate **668990-77-0P**, 3-tert-Butyl-6-[4-(2,5-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine **668990-78-1P**, 3-tert-Butyl-6-[4-(2,4-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine **668990-97-4P**, 3-Isopropyl-6-[4-(2,4-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(p38 kinase inhibitor; preparation of alkyldifluorophenoxyazolyltriazolopyridines as MAP kinases, in particular p38 kinase inhibitors)


10649227

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(3,4-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 668981-03-1 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,6-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 668981-04-2 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 668981-05-3 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 668981-02-0


CMF C18 H14 F2 N4 O

10649227



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 668981-06-4 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)


CM 1

CRN 668981-02-0
CMF C18 H14 F2 N4 O



CM 2


CRN 104-15-4
CMF C7 H8 O3 S






RN 668981-07-5 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, sulfate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 668981-02-0
CMF C18 H14 F2 N4 O




CM 2

CRN 7664-93-9
CMF H2 O4 SRN 668990-77-0 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)RN 668990-78-1 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,4-difluorophenyl)-5-oxazolyl]-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)RN 668990-97-4 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,4-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:372880 CAPLUS
 DN 140:391284
 TI Preparation of cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines as potent inhibitors of MAP kinases, preferably p38 kinase
 IN Dombroski, Mark A.; Letavic, Michael A.; McClure, Kim F.
 PA Pfizer Inc, USA
 SO U.S. Pat. Appl. Publ., 24 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1
 PATENT NO. KIND DATE APPLICATION NO. DATE

 PI US 2004087615 A1 20040506 US 2003-649255 20030827
 PRAI US 2002-407489P P 20020830
 GI



AB The title compds. [I; R1 = F; s = 2; R2 = (un)substituted cycloalkyl] which are potent inhibitors of MAP kinases, preferably p38 kinase, and therefore useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders, were prepared. E.g., a multi-step synthesis of II, starting from 2,5-dibromopyridine, was given. The pharmaceutical composition comprising the compound I is claimed.
 IT **668990-79-2P**, 3-Cyclopropyl-6-[4-(2,4-difluorophenyl)oxazol-5-yl][1,2,4]triazolo[4,3-a]pyridine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines as potent inhibitors of MAP kinases, preferably p38 kinase)
 RN 668990-79-2 CAPLUS
 CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclopropyl-6-[4-(2,4-difluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




IT **668990-83-8P**, 3-Cyclopropyl-6-[4-(2,5-difluorophenyl)oxazol-5-yl][1,2,4]triazolo[4,3-a]pyridine **668990-84-9P**, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-(1-methylcyclopropyl)[1,2,4]triazolo[4,3-a]pyridine **668990-85-0P**, 6-[4-(2,4-Difluorophenyl)oxazol-5-yl]-3-(1-methylcyclopropyl)[1,2,4]triazolo[4,3-a]pyridine **668990-86-1P**, 3-Cyclobutyl-6-[4-(2,5-difluorophenyl)oxazol-5-yl][1,2,4]triazolo[4,3-a]pyridine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines as potent inhibitors of MAP kinases, preferably p38 kinase)


RN 668990-83-8 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclopropyl-6-[4-(2,5-difluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 668990-84-9 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylcyclopropyl)- (9CI) (CA INDEX NAME)




RN 668990-85-0 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,4-difluorophenyl)-5-oxazolyl]-3-(1-methylcyclopropyl)- (9CI) (CA INDEX NAME)




RN 668990-86-1 CAPLUS
 CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclobutyl-6-[4-(2,5-difluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:331789 CAPLUS
 DN 140:357352
 TI Preparation of 3-alkyl-6-[4-(trifluorophenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridines as potent inhibitors of MAP kinases
 IN Dombroski, Mark A.; Letavic, Michael A.; McClure, Kim F.
 PA Pfizer Inc, USA
 SO U.S. Pat. Appl. Publ., 25 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|------------|----------|-----------------|----------|
| PI | US 2004077682 | A1 | 20040422 | US 2003-649265 | 20030827 |
| PRAI | US 2002-407089P | P | 20020830 | | |
| OS | MARPAT | 140:357352 | | | |
| GI | | | | | |



AB The title compds. [I; R1 = F; s = 3; R2 = alkyl optionally substituted by halo, OH, alkoxy, etc.] which are potent inhibitors of MAP kinases, preferably p38 kinase, were prepared. Thus, reacting [α -(p-toluenesulfonyl)-2,4,5-trifluorobenzyl]isonitrile with 3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine-6-carboxaldehyde (prepns.

given) in the presence of K₂CO₃ in MeCN at 70°C for 22 h afforded 48% II. All compds. I that were tested had an IC₅₀ of <10 μM in the TNFα and MAPKAP in vitro assays and ED₅₀ of <50 mg/kg in the in vivo TNFα assay. The compds. I are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders. The pharmaceutical composition comprising the compound I is claimed.

IT 668990-87-2P 668990-90-7P 668990-91-8P


668990-92-9P 668990-93-0P 668990-94-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-alkyl-6-[4-(trifluorophenyl)-oxazol-5-yl]-
[1,2,4]triazolo[4,3-a]pyridines as potent inhibitors of MAP kinases)


RN 668990-87-2 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(2,4,5-
trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 668990-90-7 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(2,3,4-
trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 668990-91-8 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(2,3,5-
trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 668990-92-9 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(2,4,6-
trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 668990-93-0 CAPLUS
 CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(3,4,5-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 668990-94-1 CAPLUS
 CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1,1-dimethylethyl)-6-[4-(2,4,5-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:203834 CAPLUS
 DN 140:235722
 TI Preparation of 6-[4-(di- or trifluorophenyl)oxazol-5-yl][1,2,4]triazolo[4,3-a]pyridine as inhibitors of mitogen-activated protein (MAP) kinases
 IN Dombroski, Mark Anthony; Letavic, Michael Anthony; McClure, Kim Francis
 PA Pfizer Products Inc., USA
 SO PCT Int. Appl., 87 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|--|----------|-----------------|----------|
| PI | WO 2004020440 | A1 | 20040311 | WO 2003-IB3847 | 20030819 |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |


RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004053958 A1 20040318 US 2003-649236 20030827

PRAI US 2002-407177P P 20020830

OS MARPAT 140:235722

GI




AB The present invention relates to novel triazolo-pyridines of the formula (I) [wherein R1 is fluoro; m = 2,3; R2 is C3-6 cycloalkyl optionally substituted by one or two moieties independently selected from the group consisting of halo, C1-4 alkyl, hydroxy, C1-6 alkoxy and C1-6 alkyl-CO-O; or R2 is C1-6 alkyl optionally substituted by one or two moieties independently selected from the group consisting of halo, C1-6 alkyl, hydroxy, C1-6 alkoxy and C1-6 alkyl-CO-O; with the proviso that said compound of this formula cannot be 6-[4-(2,4-difluorophenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine or 6-[4-(3,4-difluorophenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine] or pharmaceutically acceptable salt thereof; to intermediates for their preparation, and to pharmaceutical compns. containing them and to their medicinal use. The compds. I are potent inhibitors of mitogen-activated protein (MAP) kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders. Thus, a mixture of [α -(p-toluenesulfonyl)-2,6-difluorobenzyl]isonitrile (1.79 g, 5.84 mmol), 3-isopropyl-[1,2,4]triazolo[4,3-a]-6-pyridinecarboxaldehyde (1.10 g, 5.84 mmol), potassium carbonate (1.05 g, 7.59 mmol) and acetonitrile (17.5 mL) was refluxed for 22 h to give, after workup and silica gel chromatog., 6-[4-(2,6-difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine as a yellow solid. A tablet formulation containing 6-[4-(2,5-difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine was prepared, which can be administered to a human from one to four times a day for inhibiting cartilage damage or treating osteoarthritis.

IT **668981-02-0P**

RL: PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(X-ray crystallog. data and polymorphism; preparation of [(di- and trifluorophenyl)oxazolyl]triazolopyridine as p38 kinase inhibitors and therapeutic agents)

RN 668981-02-0 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



IT **668990-79-2P**, 3-Cyclopropyl-6-[4-(2,4-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (intermediate; preparation of [(di- and trifluorophenyl)oxazolyl]triazolopyridine as p38 kinase inhibitors and therapeutic agents)

RN 668990-79-2 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclopropyl-6-[4-(2,4-difluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




IT **668981-03-1P**, 6-[4-(2,6-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine **668981-04-2P**, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine hydrochloride **668981-05-3P**, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine methanesulfonate **668981-06-4P**, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine p-toluenesulfonate **668981-07-5P**, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine sulfate **668990-77-0P**, 3-tert-Butyl-6-[4-(2,5-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine **668990-78-1P**, 3-tert-Butyl-6-[4-(2,4-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine **668990-83-8P**, 3-Cyclopropyl-6-[4-(2,5-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine **668990-84-9P**, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-(1-methylcyclopropyl)-[1,2,4]triazolo[4,3-a]pyridine **668990-85-0P**, 6-[4-(2,4-Difluorophenyl)oxazol-5-yl]-3-(1-methylcyclopropyl)-[1,2,4]triazolo[4,3-a]pyridine **668990-86-1P**, 3-Cyclobutyl-6-[4-(2,5-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine **668990-87-2P**, 3-Isopropyl-6-[4-(2,4,5-trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine **668990-90-7P**, 3-Isopropyl-6-[4-(2,3,4-trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine **668990-91-8P**, 3-Isopropyl-6-[4-(2,3,5-trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine **668990-92-9P**, 3-Isopropyl-6-[4-(2,4,6-trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine **668990-93-0P**, 3-Isopropyl-6-[4-(3,4,5-trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine **668990-94-1P**, 3-tert-Butyl-6-[4-(2,4,5-trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine **668990-95-2P**, 3-Cyclopropyl-6-[4-(2,4,5-trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine **668990-96-3P**, 3-(1-Methylcyclopropyl)-6-[4-(2,4,5-trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine **668990-97-4P**, 3-Isopropyl-6-[4-(2,4-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

10649227

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of [(di- and trifluorophenyl)oxazolyl]triazolopyridine as p38
kinase inhibitors and therapeutic agents)


RN 668981-03-1 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,6-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 668981-04-2 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 668981-05-3 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 668981-02-0

CMF C18 H14 F2 N4 O




CM 2


CRN 75-75-2

CMF C H4 O3 S


10649227




RN 668981-06-4 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)
CM 1
CRN 668981-02-0
CMF C18 H14 F2 N4 O



CM 2
CRN 104-15-4
CMF C7 H8 O3 S




RN 668981-07-5 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, sulfate (1:1) (9CI) (CA INDEX NAME)
CM 1
CRN 668981-02-0
CMF C18 H14 F2 N4 O




CM 2
CRN 7664-93-9
CMF H2 O4 S


10649227




RN 668990-77-0 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 668990-78-1 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,4-difluorophenyl)-5-oxazolyl]-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 668990-83-8 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclopropyl-6-[4-(2,5-difluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 668990-84-9 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylcyclopropyl)- (9CI) (CA INDEX NAME)


10649227




RN 668990-85-0 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,4-difluorophenyl)-5-oxazolyl]-3-(1-methylcyclopropyl)- (9CI) (CA INDEX NAME)




RN 668990-86-1 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclobutyl-6-[4-(2,5-difluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 668990-87-2 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(2,4,5-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 668990-90-7 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(2,3,4-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 668990-91-8 CAPLUS
 CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(2,3,5-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 668990-92-9 CAPLUS
 CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(2,4,6-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 668990-93-0 CAPLUS
 CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(3,4,5-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 668990-94-1 CAPLUS
 CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1,1-dimethylethyl)-6-[4-(2,4,5-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)

10649227




RN 668990-95-2 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclopropyl-6-[4-(2,4,5-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 668990-96-3 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylcyclopropyl)-6-[4-(2,4,5-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 668990-97-4 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,4-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




RE.CNT 2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:203832 CAPLUS
 DN 140:235721
 TI Novel processes and intermediates for preparing [1,2,4]triazolo[4,3-a]pyridines
 IN Buzon, Richard Allen Sr.; Castaldi, Michael James; Li, Zhengong Bryan;
 Ripin, David Harold Brown; Tao, Yong
 PA Pfizer Products Inc., USA
 SO PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|---|----------|
| PI WO 2004020438 | A2 | 20040311 | WO 2003-IB3669 | 20030818 |
| | | | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | |
| | | | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | |
| US 2004053959 | A1 | 20040318 | US 2003-649247 | 20030827 |
| PRAI US 2002-407085P | P | 20020830 | | |
| OS CASREACT 140:235721; MARPAT 140:235721 | | | | |
| GI | | | | |




AB The present invention relates and intermediates to a novel process for preparing triazolo-pyridines of the formula (I) [R1 = H, cyano, each (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, Ph, C1-10 heteroaryl, C1-10 heterocyclyl or NH2; R3 = halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, perhalo-C1-6 alkyl, Ph, C1-10 heteroaryl, C1-10 heterocyclyl, C3-10 cycloalkyl, HO, C1-6 alkoxy, perhalo-C1-10 alkoxy, PhO, C1-10 heteroaryloxy, C1-10 heterocyclyoxy-C3-10 cycloalkyoxy, C1-6 alkylthio, C1-16 alkylsulfonyl, C1-6 alkylsulfamoyl, amino, mono - or di(C1-6 alkyl)amino, C1-6 sulfonylamino, C1-6 alkyl-carbonylamino, etc.; or two adjacent R2 taken together with the carbon atoms to which they are attached to form a five to six membered carbocyclic or heterocyclic ring; m = an integer from 0-5; R4 = H, F, Cl, R5-B-(CH2)n-; n = an integer from 0-6; B = a bond, (CHR6), O, S, SO2, CO, O-CO, CO-O, CO-NR6, R6N, R6NSO2, R6NCO, SO2NR6, R6NCONR7, O-CONR6 or R6NCO-O; R5 = H, CF3, cyano, each (un)substituted Ph, C1-10 heterocyclyl, C1-10 heteroaryl, or C3-10 cycloalkyl, etc.; R6 = H, C1-6 alkylsulfonyl, C1-6 alkyl] or acceptable salts thereof, e.g., comprising reacting 6-(oxazol-5-yl)[1,2,4]triazolo[4,3-a]pyridines (II) (L = a leaving group and R1 and R4 are as defined above) with phenylboronic acids (III) and a transition metal catalyst. The compds. I prepared by the methods of the

present invention are potent inhibitors of mitogen-activated protein (MAP) kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders. Thus, 6-(4-bromooxazol-5-yl)-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine (33.0 g, 0.107 mol), 2,5-difluorophenylboronic acid (25.34 g, 0.1605 mol), Pd(PPh₃)₄ (12.36 g, 0.0107 mol), Et₃N (22.37 mL, 0.1605 mol), 2B ethanol (495 mL), and water (33 mL), were added to a 2 L 4 neck round bottom flask (equipped with mech. stirring, nitrogen, heating mantle, temperature controller, and a condenser), stirred while heating to 65 to 70°, and kept stirring overnight at apprx. 70°. Two addnl. difluorophenylboronic acid (8.5 g, 0.054 mol) and Et₃N (7.53 mL, 0.054 mol), were added and each time the reaction was allowed to proceed overnight at 70°. Toluene (30 mL) was added and the reaction was allowed to go overnight once again at 70°, treated with H₂O (495 mL), and pot-granulated for 4 h at 20 to 25°. The solids were collected by vacuum filtration, washed with 2B ethanol/H₂O (50:50) (25 mL of each), and dried in a vacuum oven at 45° for 4 h under full vacuum to afford 14.4 g 3-isopropyl-6-[4-(2,5-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine (40.6% yield, 93.4% purity by HPLC).

IT **668981-02-0P**, 6-[4-(2,5-difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine
 RL: IMF (Industrial manufacture); PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of triazolopyridines as p38 kinase inhibitors by Suzuki coupling of phenylboronic acid with (bromooxazolyl)triazolopyridine derivative or cyclocondensation of α -tosylbenzyl isonitrile with triazolopyridinecarboxaldehyde)

RN 668981-02-0 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



IT **668981-03-1P**, 6-[4-(2,6-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine **668981-04-2P**, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine hydrochloride **668981-05-3P**, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine methanesulfonate **668981-06-4P**, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine p-toluenesulfonate **668981-07-5P**, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine sulfate
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of triazolopyridines as p38 kinase inhibitors by Suzuki coupling of phenylboronic acid with (bromooxazolyl)triazolopyridine derivative or cyclocondensation of α -tosylbenzyl isonitrile with triazolopyridinecarboxaldehyde)


RN 668981-03-1 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,6-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 668981-04-2 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 668981-05-3 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 668981-02-0


CMF C18 H14 F2 N4 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 668981-06-4 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

10649227


CM 1

CRN 668981-02-0
CMF C18 H14 F2 N4 O



CM 2

CRN 104-15-4
CMF C7 H8 O3 S




RN 668981-07-5 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, sulfate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 668981-02-0
CMF C18 H14 F2 N4 O



CM 2

CRN 7664-93-9
CMF H2 O4 S




L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:716275 CAPLUS
DN 137:232658

TI Preparation of 6-(phenylheterocyclyl)-[1,2,4]triazolo[4,3-a]pyridines as anti-inflammatory agents
 IN Dombroski, Mark Anthony; Duplantier, Allen Jacob; Laird, Ellen Ruth; Letavic, Michael Anthony; McClure, Kim Francis
 PA Pfizer Products Inc., USA
 SO PCT Int. Appl., 111 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2002072579 | A1 | 20020919 | WO 2002-IB424 | 20020208 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | EP 1370559 | A1 | 20031217 | EP 2002-710260 | 20020208 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | EE 200300437 | A | 20040216 | EE 2003-437 | 20020208 |
| | BR 200207990 | A | 20040427 | BR 2002-7990 | 20020208 |
| | US 2003096838 | A1 | 20030522 | US 2002-94760 | 20020311 |
| | US 6696464 | B2 | 20040224 | | |
| | NO 2003003969 | A | 20031013 | NO 2003-3969 | 20030908 |
| PRAI | US 2001-274840P | P | 20010309 | | |
| | WO 2002-IB424 | W | 20020208 | | |
| OS | MARPAT 137:232658 | | | | |
| GI | | | | | |



AB Title compds. I [wherein Het = (un)substituted pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, or isothiazolyl; R2 = H, alkenyl, alkynyl, or (un)substituted (cyclo)alkyl, Ph, heteroaryl, or heterocyclyl, or amino; R3 = halo, (cyclo)alkyl(oxy), (perhalo)alkyl, alkenyl, alkynyl, Ph, heteroaryl(oxy), heterocyclyl(oxy), OH, (perhalo)alkoxy, PhO, alkylthio, alkylsulfonyl, alkylaminosulfonyl, NO2, (un)substituted amino, carbamoyl, etc.; n = 0-5; or pharmaceutically acceptable salts thereof] were prepared as potent inhibitors of MAP kinases, preferably p38 kinase (no data). For example, 6-chloronicotinic acid was condensed with N,O-dimethylhydroxylamine-HCl (96%). Treatment of the amide with (i-Bu)2AlH gave the aldehyde (24%), which was coupled with (phenyl)(p-tolylsulfonyl)methylisocyanide to afforded 2-chloro-5-(4-phenyloxazol-5-yl)pyridine (71%). Conversion to the hydrazine (100%), followed by coupling with isobutyl chloride and cyclization using POC13 (32%), produced II. I are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases, and other disorders (no data).

IT **459447-61-1P**, 3-Isopropyl-6-(4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-64-4P**, 3-Ethyl-6-(4-m-tolylloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-66-6P**, 3-Cyclopropyl-6-[4-(4-fluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine **459447-67-7P**, 3-Cyclobutyl-6-[4-(4-fluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine **459447-69-9P**, 3-Difluoromethyl-6-(4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-71-3P**, 3-(Isoxazol-5-yl)-6-(4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-72-4P**, 6-(4-Phenyloxazol-5-yl)-3-(2,2,2-trifluoroethyl)-


[1,2,4]triazolo[4,3-a]pyridine **459447-73-5P**,
 3-Cyclobutyl-6-(4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-74-6P**, 3-Cyclopropyl-6-(4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-75-7P**,
 3-Ethyl-6-(4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-76-8P**, 3-Ethyl-6-[4-(4-fluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine **459447-77-9P**,
 6-[4-(4-Fluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine **459447-78-0P**, 3-Cyclobutyl-6-(4-m-tolyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-79-1P**,
 3-Isopropyl-6-(4-m-tolyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-80-4P**, 6-[4-(4-Fluoro-3-methylphenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine **459447-82-6P**,
 3-Cyclopropyl-6-[4-(4-fluoro-3-methylphenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine **459447-83-7P**,
 6-[4-(4-Fluorophenyl)oxazol-5-yl]-3-phenyl-[1,2,4]triazolo[4,3-a]pyridine **459447-84-8P**, 3-Isopropyl-6-(2-methyl-4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-88-2P**,
 6-[4-(4-Fluorophenyl)-2-methyloxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine **459447-89-3P**, [6-[4-(4-Fluorophenyl)oxazol-5-yl]-[1,2,4]triazol[4,3-a]pyridin-3-yl]acetic acid ethyl ester **459447-90-6P**, 3-(2-Chlorophenyl)-6-[4-(m-tolyl)oxazol-5-yl]-[1,2,4]triazol[4,3-a]pyridine **459447-91-7P**, 6-[4-(2-Fluoro-5-methylphenyl)oxazol-5-yl]-[1,2,4]triazol[4,3-a]pyridine **459447-92-8P** **459447-93-9P**, 3-(2-Fluorophenyl)-6-[4-(m-tolyl)oxazol-5-yl]-[1,2,4]triazol[4,3-a]pyridine **459447-94-0P**,
 [6-[4-(4-Fluorophenyl)oxazol-5-yl]-[1,2,4]triazol[4,3-a]pyridin-3-yl]dimethylamine **459447-95-1P**, 6-[4-(4-Fluoro-3-methylphenyl)oxazol-5-yl]-3-phenyl-[1,2,4]triazol[4,3-a]pyridine **459447-96-2P**, 6-[4-(3-Chloro-4-fluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazol[4,3-a]pyridine **459447-97-3P**,
 6-[4-(3-Fluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazol[4,3-a]pyridine **459447-98-4P**, 3-(2-Chlorophenyl)-6-[4-(4-fluorophenyl)oxazol-5-yl]-[1,2,4]triazol[4,3-a]pyridine **459448-00-1P**, 6-[4-(3,4-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazol[4,3-a]pyridine **459448-01-2P**, 6-[4-(4-Fluorophenyl)-2-methyloxazol-5-yl]-3-phenyl-[1,2,4]triazol[4,3-a]pyridine **459448-02-3P**, 6-[4-(3-Fluorophenyl)oxazol-5-yl]-3-phenyl-[1,2,4]triazol[4,3-a]pyridine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(anti-inflammatory agent; preparation of (phenylheterocyclyl)triazolopyridines as anti-inflammatory agents)


RN 459447-61-1 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-(4-phenyl-5-oxazolyl)-(9CI) (CA INDEX NAME)




RN 459447-64-4 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-ethyl-6-[4-(3-methylphenyl)-5-oxazolyl]-(9CI) (CA INDEX NAME)




10649227


RN 459447-66-6 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclopropyl-6-[4-(4-fluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 459447-67-7 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclobutyl-6-[4-(4-fluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 459447-69-9 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(difluoromethyl)-6-(4-phenyl-5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 459447-71-3 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(5-isoxazolyl)-6-(4-phenyl-5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 459447-72-4 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-(4-phenyl-5-oxazolyl)-3-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 459447-73-5 CAPLUS
 CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclobutyl-6-(4-phenyl-5-oxazolyl)- (9CI)
 (CA INDEX NAME)




RN 459447-74-6 CAPLUS
 CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclopropyl-6-(4-phenyl-5-oxazolyl)-
 (9CI) (CA INDEX NAME)



RN 459447-75-7 CAPLUS
 CN 1,2,4-Triazolo[4,3-a]pyridine, 3-ethyl-6-(4-phenyl-5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 459447-76-8 CAPLUS
 CN 1,2,4-Triazolo[4,3-a]pyridine, 3-ethyl-6-[4-(4-fluorophenyl)-5-oxazolyl]-
 (9CI) (CA INDEX NAME)



10649227


RN 459447-77-9 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(4-fluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 459447-78-0 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclobutyl-6-[4-(3-methylphenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 459447-79-1 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(3-methylphenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 459447-80-4 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(4-fluoro-3-methylphenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




10649227


RN 459447-82-6 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclopropyl-6-[4-(4-fluoro-3-methylphenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 459447-83-7 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(4-fluorophenyl)-5-oxazolyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 459447-84-8 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-(2-methyl-4-phenyl-5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 459447-88-2 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(4-fluorophenyl)-2-methyl-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 459447-89-3 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine-3-acetic acid, 6-[4-(4-fluorophenyl)-5-oxazolyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 459447-90-6 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(2-chlorophenyl)-6-[4-(3-methylphenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 459447-91-7 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2-fluoro-5-methylphenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 459447-92-8 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(4-fluorophenyl)-5-oxazolyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



10649227


RN 459447-93-9 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(2-fluorophenyl)-6-[4-(3-methylphenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 459447-94-0 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridin-3-amine, 6-[4-(4-fluorophenyl)-5-oxazolyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 459447-95-1 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(4-fluoro-3-methylphenyl)-5-oxazolyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 459447-96-2 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(3-chloro-4-fluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



10649227


RN 459447-97-3 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(3-fluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 459447-98-4 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(2-chlorophenyl)-6-[4-(4-fluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 459448-00-1 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(3,4-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 459448-01-2 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(4-fluorophenyl)-2-methyl-5-oxazolyl]-3-phenyl- (9CI) (CA INDEX NAME)



10649227

RN 459448-02-3 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(3-fluorophenyl)-5-oxazolyl]-3-phenyl-
(9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT